These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 38032111)

  • 1. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer.
    Kos FJ; Frankel P; Cristea M; Eng M; Tinsley R; Dempsey S; Ruel N; Stewart D; Dellinger TH; Diamond DJ
    Cancer Res Commun; 2023 Dec; 3(12):2585-2595. PubMed ID: 38032111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
    Hardwick NR; Frankel P; Ruel C; Kilpatrick J; Tsai W; Kos F; Kaltcheva T; Leong L; Morgan R; Chung V; Tinsley R; Eng M; Wilczynski S; Ellenhorn JDI; Diamond DJ; Cristea M
    Clin Cancer Res; 2018 Mar; 24(6):1315-1325. PubMed ID: 29301826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.
    Chung V; Kos FJ; Hardwick N; Yuan Y; Chao J; Li D; Waisman J; Li M; Zurcher K; Frankel P; Diamond DJ
    Clin Transl Oncol; 2019 Mar; 21(3):363-372. PubMed ID: 30094792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
    Liao JB; Gwin WR; Urban RR; Hitchcock-Bernhardt KM; Coveler AL; Higgins DM; Childs JS; Shakalia HN; Swensen RE; Stanton SE; Tinker AV; Wahl TA; Ancheta RG; McGonigle KF; Dai JY; Disis ML; Goff BA
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
    Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.
    Hardwick NR; Carroll M; Kaltcheva T; Qian D; Lim D; Leong L; Chu P; Kim J; Chao J; Fakih M; Yen Y; Espenschied J; Ellenhorn JD; Diamond DJ; Chung V
    Clin Cancer Res; 2014 Sep; 20(17):4459-70. PubMed ID: 24987057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming immunosuppression to enhance a p53MVA vaccine.
    Hardwick N; Chung V; Cristea M; Ellenhorn JD; Diamond DJ
    Oncoimmunology; 2014 Nov; 3(10):e958949. PubMed ID: 25941580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
    Herzog TJ; Hays JL; Barlin JN; Buscema J; Cloven NG; Kong LR; Tyagi NK; Lanneau GS; Long BJ; Marsh RL; Seward SM; Starks DC; Welch S; Moore KN; Konstantinopoulos PA; Gilbert L; Monk BJ; O'Malley DM; Chen X; Dalal R; Coleman RL; Sehouli J
    Future Oncol; 2023 Jul; 19(23):1577-1591. PubMed ID: 37334673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.
    Yuan Y; Kos FJ; He TF; Yin HH; Li M; Hardwick N; Zurcher K; Schmolze D; Lee P; Pillai RK; Chung V; Diamond DJ
    Oncoimmunology; 2017; 6(12):e1363138. PubMed ID: 29209571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
    Overman M; Javle M; Davis RE; Vats P; Kumar-Sinha C; Xiao L; Mettu NB; Parra ER; Benson AB; Lopez CD; Munugalavadla V; Patel P; Tao L; Neelapu S; Maitra A
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Nijman HW; van Poelgeest MI; van Erkel AR; Smit VT; Daemen TA; van der Hoeven JJ; Melief CJ; Welters MJ; Kroep JR; van der Burg SH
    Oncotarget; 2015 Oct; 6(31):32228-43. PubMed ID: 26334096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
    Varga A; Piha-Paul S; Ott PA; Mehnert JM; Berton-Rigaud D; Morosky A; Yang P; Ruman J; Matei D
    Gynecol Oncol; 2019 Feb; 152(2):243-250. PubMed ID: 30522700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer.
    Andrikopoulou A; Liontos M; Skafida E; Koutsoukos K; Apostolidou K; Kaparelou M; Rouvalis A; Bletsa G; Dimopoulos MA; Zagouri F
    Int J Gynecol Cancer; 2023 Apr; 33(4):571-576. PubMed ID: 36604119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
    How JA; Jazaeri A; Westin SN; Sood AK; Ramondetta LM; Xu M; Abonofal A; Karp DD; Subbiah V; Stephen B; Rodon JA; Yang F; Naing A
    Invest New Drugs; 2021 Jun; 39(3):829-835. PubMed ID: 33415580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
    Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
    Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid.
    Portnow J; Wang D; Blanchard MS; Tran V; Alizadeh D; Starr R; Dodia R; Chiu V; Brito A; Kilpatrick J; McNamara P; Forman SJ; Badie B; Synold TW; Brown CE
    JAMA Oncol; 2020 Dec; 6(12):1947-1951. PubMed ID: 33030521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
    Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study.
    Jung HA; Park S; Choi YL; Lee SH; Ahn JS; Ahn MJ; Sun JM
    Clin Cancer Res; 2022 Jun; 28(11):2321-2328. PubMed ID: 35101883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.
    Hong JY; Cho HJ; Sa JK; Liu X; Ha SY; Lee T; Kim H; Kang W; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Park HC; Kang TW; Rhim H; Lee SJ; Cristescu R; Lee J; Paik YH; Lim HY
    Genome Med; 2022 Jan; 14(1):1. PubMed ID: 34986867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.